{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335092","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2026-08-05T20:09:46+00:00","discovered_at":"2026-08-05T20:11:00.233951+00:00","generated_at":"2026-08-05T20:12:00.275972+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences Q2 revenue $23.4M (+20% YoY); raises FY2026 revenue guidance to $88-92M","bullets":["Q2 revenue $23.4M (+20% YoY); IG $20.7M (+8%), IDE record $2.7M (+704%).","Net loss improved to $4.4M ($0.08 loss per share) from $11.9M ($0.23) YoY.","Raised FY2026 revenue guidance to $88-92M (prior $83-89M); reduced adjusted opex guidance to $92-94M.","Cash usage $5.2M in Q2, down 28% YoY; cash $79.8M; debt $40M.","FDA 510(k) clearance for OMNI Ultra; Aetna coverage for implant-free glaucoma procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335092","json":"https://secwatch.observer/filing/0001193125-26-335092.json","markdown":"https://secwatch.observer/filing/0001193125-26-335092.md","text":"https://secwatch.observer/filing/0001193125-26-335092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526335092/0001193125-26-335092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526335092/sght-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:12:00.275972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}